Clinical trials: BCLC Stage A Hepatocellular Carcinoma
NSCLC Stage IIIB, NSCLC Stage IV
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, Hepatocellular Carcinoma by BCLC Stage, Lung Cancer
- Trial name
- NCT03515252
- Testing
- Immune Killer Cells (IKC)
- Volunteers
- 20 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
This phase I trial studies the side effects and best dose of Chinese herbal formulation PHY906 when given together with sorafenib tosylate in treating patients with advanced liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Advanced Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma
- Trial name
- NCT01666756
- Testing
- Chinese herbal formulation PHY906, sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
HCC - Hepatocellular Carcinoma
Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma
This study aims to investigate the recurrence patterns and cost-effectiveness of robotic-assisted, laparoscopic, and open liver resections in patients with early-stage (BCLC 0/A) hepatocellular carcinoma.
- Trial name
- NCT06776185
- Testing
- Liver Surgery
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Chen Xiaoping
Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
This prospective, multicenter, phase II randomized controlled trial compares the efficacy and safety of SBRT combined with systemic therapy versus systemic therapy alone in BCLC stage C hepatocellular carcinoma (HCC).
- Trial name
- NCT07274774
- Testing
- Systemic therapy, Radiotherapy
- Where
- China
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
- Trial name
- NCT03851913
- Testing
- TAI
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC), Emotional Distress
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
This study is a multicenter, prospective, observational clinical trial designed to evaluate the impact of baseline emotional status on the clinical outcomes of patients with BCLC stage B/C hepatocellular carcinoma undergoing HAIC…
- Conditions
- Hepatocellular Carcinoma (HCC), Emotional Distress, HAIC(Hepatic Artery Infusion Chemotherapy), Immunotherapy
- Trial name
- NCT07436845
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced stage).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04442581
- Testing
- Cabozantinib S-malate, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
This clinical trial studies positron emission tomography (PET)-computed tomography (CT) in determining the radiation dose delivered with radioactive spheres to patients with liver metastasis or primary liver or biliary cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02088775
- Testing
- PET scan, CT Scan, hepatic artery embolization
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Fox Chase Cancer Center
Hepatocellular Carcinoma
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC.
- Trial name
- NCT03780049
- Testing
- HAIC of FOLFOX, H101
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Metformin Plus Sorafenib for Advanced HCC
Metformin is a widely used oral drug for type 2 diabetes and its antitumor effects have got much more attentions recently. It has been shown that metformin exerts anti-cancer activities in several cancers, including primary liver…
- Trial name
- NCT02672488
- Testing
- Sorafenib, Metformin
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma by BCLC Stage
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma
Anatomical liver resection was widely accepted as first line curative therapy for hepatocellular carcinoma. However, number of retrospective clinical studies showed no priority of anatomical resection for hepatocellular, compared…
- Trial name
- NCT03652896
- Testing
- anatomical liver resection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huazhong University of Science and Technology
Advanced Hepatocellular Carcinoma
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
- Trial name
- SIERRA (NCT05883644)
- Testing
- Durvalumab, Tremelimumab
- Where
- 40 sites in United States, France and 8 more
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Advanced Hepatocellular Carcinoma
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced…
- Trial name
- NCT04000737
- Testing
- Sorafenib+YIV-906
- Where
- 24 sites in United States, China and 2 more
- Volunteers
- 62 people
- Sponsor
- Yiviva Inc.
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma
- Trial name
- NCT02940496
- Testing
- Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
C-staged Hepatocellular Carcinoma in BCLC Classification
A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (Triplet-combined Therapy) for C-staged Hepatocellular Carcinoma in BCLC…
- Trial name
- TRIPLET (NCT04191889)
- Testing
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular…
- Conditions
- HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma, Lenvatinib
- Trial name
- NCT06631326
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 244 people
- Sponsor
- First Hospital of China Medical University
Radiomics, Hepatocellular Carcinoma (HCC)
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
The goal of this observational study is to explore the role of prediction of microvascular invasion by radiomics based on pre-treatment magnetic resonance imaging for guiding treatment of Barcelona Clinic Liver Cancer stage B…
- Conditions
- Radiomics, Hepatocellular Carcinoma (HCC), Transcatheter Arterial Chemoembolization (TACE), Microvascular Invasion (MVI)
- Trial name
- NCT05889949
- Testing
- Sorafenib, Lenvatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Long-term Effects of Cancer Treatment
A Long-term Survival Analysis of Different Surgical Method in Early Hepatocellular Carcinoma
The investigators established three prospective cohorts of patients with BCLC stage 0-A HCC, based on different surgical approaches (open, laparoscopic and robotic).
- Trial name
- NCT05117047
- Testing
- liver resection
- Where
- China
- Volunteers
- 369 people
- Sponsor
- Chen Xiaoping
HCC, Radiofrequency Ablation
Combined Treatment of RFA and Sorafenib on Recurrent HCC
RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC.
- Conditions
- HCC, Radiofrequency Ablation, Sorafenib
- Trial name
- REPEAT (NCT01470495)
- Testing
- RFA + Sorafenib, RFA
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Southwest Hospital, China
Hepatocellular Carcinoma by BCLC Stage
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with BCLC-B stage hepatocellular carcinoma beyond…
- Trial name
- B-TACE (NCT05883176)
- Testing
- Bevacizumab Biosimilar QL 1101
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University